COMPANY

Integral Molecular

HQ: Philadelphia, PA source · integralmolecular.com ↗ · Mid-Atlantic

Service / Tools company

5 open jobs · last seen Oct 23, 2026 · 51 sources

Keywords: research tools

Location: Philadelphia, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

5Open jobs 50NIH grants

Hiring

Title	Location (from posting)	Employer posted	First seen
Commercial Operations Specialist	Philadelphia, PA	Oct 19, 2026	Oct 20, 2026
Digital Marketing Manager	Philadelphia, PA	Sep 25, 2026	Oct 5, 2026
Product Analyst/Specialist - Biotech	Philadelphia, PA	Sep 17, 2026	Oct 5, 2026
Research Technician	Philadelphia, PA	Oct 11, 2024	Oct 5, 2026
Research Associate	Philadelphia, PA	Aug 22, 2024	Oct 5, 2026

See all 5 jobs

Funding and NIH signals

NIH award NIH awarded $879K (SBIR commercialization 5SB1GM156044-03, continuation, notice Sep 8, 2026); 3 NIH awards totaling $2.05M in the last 12 months; since then posted 2 roles. NIH RePORTER 5SB1GM156044-03 (Sep 8, 2026)
Evidence (3 events)
- Sep 8, 2026 · NIH RePORTER 5SB1GM156044-03
  Organization: INTEGRAL MOLECULAR; City/State: PHILADELPHIA, PA; Project number: 5SB1GM156044-03; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-08; FY total cost (award amount): 879255; Administering IC: National Institute of General Medical Sciences; Project title: Specificity Screening Drug Development Tool for Biotherapeutic Safety; Organization type: Domestic For-Profits
- Jul 30, 2026 · NIH RePORTER 5R44GM150317-03
  Organization: INTEGRAL MOLECULAR; City/State: PHILADELPHIA, PA; Project number: 5R44GM150317-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-30; FY total cost (award amount): 631033; Administering IC: National Institute of General Medical Sciences; Project title: High-throughput Discovery of Antibodies against Understudied Membrane Proteins using mRNA; Organization type: Domestic For-Profits
- Jun 19, 2026 · NIH RePORTER 5U24AI189369-02
  Organization: INTEGRAL MOLECULAR; City/State: PHILADELPHIA, PA; Project number: 5U24AI189369-02; Activity code: U24; Fiscal year: 2026; Award notice date: 2026-06-19; FY total cost (award amount): 541852; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Generation of Pan-reactive Antibody and Cytokine Reagents for Immunologic Analysis of Bats; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Oct 5, 2026 Board tracked Radar started tracking this company’s job board (5 open jobs at last check). source ↗

Open jobs 5

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Commercial Operations Specialist	Philadelphia, PA	Oct 19, 2026	Oct 20, 2026	Not stated
Digital Marketing Manager	Philadelphia, PA	Sep 25, 2026	Oct 5, 2026	Mid
Product Analyst/Specialist - Biotech	Philadelphia, PA	Sep 17, 2026	Oct 5, 2026	Entry
Research Technician	Philadelphia, PA	Oct 11, 2024	Oct 5, 2026	Entry
Research Associate	Philadelphia, PA	Aug 22, 2024	Oct 5, 2026	Entry

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

NIH awards 50

Annual award amounts. Total $69.5M.

Sep 8, 2026 NIH award 5SB1GM156044-03 FY2026: $879,255 awarded for that fiscal year; activity SB1 (SBIR); PI DORANZ, BENJAMIN J; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Specificity Screening Drug Development source ↗
Jul 30, 2026 NIH award 5R44GM150317-03 FY2026: $631,033 awarded for that fiscal year; activity R44 (SBIR); PI CHAMBERS, ROSS S; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. High-throughput Discovery of Antibodies a source ↗
Jun 19, 2026 NIH award 5U24AI189369-02 FY2026: $541,852 awarded for that fiscal year; activity U24 (OTHER_NIH); PI CHAMBERS, ROSS S; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Generation of Pan-reactive Antibody source ↗
2026 NIH contract (government contract; not a grant and not an investment round) 75N93024C00071-P00003-9999-1 FY2026: $1,575,147 awarded for that fiscal year; activity N01 (OTHER_NIH); PI DORANZ, BENJAMIN; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. source ↗
Aug 20, 2025 NIH award 5SB1GM156044-02 FY2025: $929,016 awarded for that fiscal year; activity SB1 (SBIR); PI DORANZ, BENJAMIN J; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Specificity Screening Drug Development source ↗
Aug 19, 2025 NIH award 1U24AI189369-01 FY2025: $495,061 awarded for that fiscal year; activity U24 (OTHER_NIH); PI CHAMBERS, ROSS S; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Generation of Pan-reactive Antibody source ↗
Aug 15, 2025 NIH award 2R44GM150317-02 FY2025: $923,143 awarded for that fiscal year; activity R44 (SBIR); PI CHAMBERS, ROSS S; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. High-throughput Discovery of Antibodies a source ↗
Jun 12, 2025 NIH award 5R43AI186556-02 FY2025: $288,515 awarded for that fiscal year; activity R43 (SBIR); PI DORANZ, BENJAMIN J; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Development of Safe and Rapid Reporter source ↗
2025 NIH contract (government contract; not a grant and not an investment round) 75N93024C00071-P00001-9999-1 FY2025: $1,722,325 awarded for that fiscal year; activity N01 (OTHER_NIH); PI n/a; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. B cell Epito source ↗
2025 NIH contract (government contract; not a grant and not an investment round) 75N93025C00019-0-9999-1 FY2025: $1,500,000 awarded for that fiscal year; activity N44 (OTHER_NIH); PI CHAMBERS, ROSS; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. ANTIBO source ↗
Sep 5, 2024 NIH award 1SB1GM156044-01 FY2024: $917,454 awarded for that fiscal year; activity SB1 (SBIR); PI DORANZ, BENJAMIN J; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Specificity Screening Drug Development source ↗
Jun 25, 2024 NIH award 1R43AI186556-01 FY2024: $288,515 awarded for that fiscal year; activity R43 (SBIR); PI DORANZ, BENJAMIN J; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Development of Safe and Rapid Reporter source ↗
May 9, 2024 NIH award 5R44CA265434-03 FY2024: $394,721 awarded for that fiscal year; activity R44 (SBIR); PI RUCKER, JOSEPH BENJAMIN; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Development of Claudin MAbs for Tr source ↗
2024 NIH contract (government contract; not a grant and not an investment round) 75N93024C00071-0-9999-1 FY2024: $1,569,483 awarded for that fiscal year; activity N01 (OTHER_NIH); PI n/a; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. B cell Epitope Di source ↗
Jun 7, 2023 NIH award 5R44CA265434-02 FY2023: $709,264 awarded for that fiscal year; activity R44 (SBIR); PI RUCKER, JOSEPH BENJAMIN; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Development of Claudin MAbs for Tr source ↗
May 4, 2023 NIH award 5R43AG076101-02 FY2023: $88,978 awarded for that fiscal year; activity R43 (SBIR); PI DORANZ, BENJAMIN J; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Identifying Regulators of Cellular Aging source ↗
Apr 20, 2023 NIH award 1R43GM150317-01 FY2023: $295,924 awarded for that fiscal year; activity R43 (SBIR); PI CHAMBERS, ROSS S; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. High-throughput Discovery of Antibodies a source ↗
2023 NIH contract (government contract; not a grant and not an investment round) 75N93019C00073-P00012-9999-1 FY2023: $1,060,517 awarded for that fiscal year; activity N01 (OTHER_NIH); PI DORANZ, BENJAMIN; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. source ↗
2023 NIH contract (government contract; not a grant and not an investment round) 75N93023C00036-0-9999-1 FY2023: $600,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI CHAMBERS, ROSS; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Reagents source ↗
Jun 15, 2022 NIH award 5R44GM113556-07 FY2022: $204,008 awarded for that fiscal year; activity R44 (SBIR); PI DORANZ, BENJAMIN J; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Next Generation Specificity Screening f source ↗
May 31, 2022 NIH award 1R44CA265434-01A1 FY2022: $599,881 awarded for that fiscal year; activity R44 (SBIR); PI RUCKER, JOSEPH BENJAMIN; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Development of Claudin MAbs for source ↗
May 18, 2022 NIH award 1R43AG076101-01 FY2022: $358,588 awarded for that fiscal year; activity R43 (SBIR); PI DORANZ, BENJAMIN J; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Identifying Regulators of Cellular Agin source ↗
Mar 17, 2022 NIH award 5R44GM112181-05 FY2022: $589,456 awarded for that fiscal year; activity R44 (SBIR); PI RUCKER, JOSEPH BENJAMIN; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Development of Kv1.3 Monoclonal An source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 75N93019C00073-P00010-9999-1 FY2022: $1,044,551 awarded for that fiscal year; activity N01 (OTHER_NIH); PI DORANZ, BENJAMIN; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. source ↗
2022 NIH contract (government contract; not a grant and not an investment round) 75N93022C00032-0-9999-1 FY2022: $600,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI RUCKER, JOSEPH; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. ADJUVANT source ↗
Sep 17, 2021 NIH award 1R43NS124421-01A1 FY2021: $474,833 awarded for that fiscal year; activity R43 (SBIR); PI RUCKER, JOSEPH BENJAMIN; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Development of Nav1.7 Monoclonal source ↗
Jun 25, 2021 NIH award 5R44GM113556-06 FY2021: $502,372 awarded for that fiscal year; activity R44 (SBIR); PI DORANZ, BENJAMIN J; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Next Generation Specificity Screening f source ↗
Mar 17, 2021 NIH award 5R44GM112181-04 FY2021: $634,330 awarded for that fiscal year; activity R44 (SBIR); PI RUCKER, JOSEPH BENJAMIN; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Development of Kv1.3 Monoclonal An source ↗
2021 NIH contract (government contract; not a grant and not an investment round) 75N93019C00073-P00006-9999-2 FY2021: $1,028,905 awarded for that fiscal year; activity N01 (OTHER_NIH); PI DORANZ, BEN; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. B-CE source ↗
Jun 30, 2020 NIH award 2R44GM113556-05 FY2020: $934,299 awarded for that fiscal year; activity R44 (SBIR); PI DORANZ, BENJAMIN J; recipient as written: INTEGRAL MOLECULAR, PHILADELPHIA, PA. Next Generation Specificity Screening f source ↗

Connect

Careers page (Oct 8, 2026)